SEC Comment Letter for PDS Biotechnology Corp (PDSB) (CIK 0001472091) (PDSB) — Nov 1, 2016
PDS Biotechnology Corp (PDSB) (CIK 0001472091)
Date: Nov. 1, 2016 · CIK: 0001472091 · Accession: 0000000000-16-099159
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214196
Letter
Mail Stop 4546 November 1 , 2016 Brian A. Leuthner President and Chief Executive Officer Edge Therapeutics, Inc. 300 Connell Drive, Suite 4000 Berkeley Heights, NJ 07922
Re: Edge Therapeutics, Inc. Registration Statement on Form S-3 Filed October 21, 2016 File No. 333-214196
Dear Mr. Leuthner :
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Michael Gershon at (202) 551 -6598 or Mary Beth Breslin at (202) 551 - 3625 with a ny questions.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4546 November 1 , 2016 Brian A. Leuthner President and Chief Executive Officer Edge Therapeutics, Inc. 300 Connell Drive, Suite 4000 Berkeley Heights, NJ 07922 Re: Edge Therapeutics, Inc. Registration Statement on Form S-3 Filed October 21, 2016 File No. 333-214196 Dear Mr. Leuthner : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Gershon at (202) 551 -6598 or Mary Beth Breslin at (202) 551 - 3625 with a ny questions. Sincerely, /s/ Mary Beth Breslin for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: David S. Rosenthal , Esq.